14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CORZ vs PATH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, UiPath, Inc. (PATH) is the stronger overall head-to-head candidate over Core Scientific, Inc. (CORZ) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). CORZ carries a Unified Composite Score of 40.2/100 (SELL) at $13.47 (16.6x Forward P/E, -2.1% operating margin), whereas PATH carries 58.3/100 (HOLD) at $13.24 (17.4x Forward P/E, 9.4% operating margin).
Growth vs. Quality Trade-Off: PATH earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. CORZ 40.2/100 SELL) and 0.86β · 30% Vol risk profile, whereas CORZ leads top-line expansion (+187.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CORZ is currently in a Breakdown options structure phase (RSI 46.9); meanwhile PATH is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Software - Infrastructure value chain with $6.8B market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment73.2% of Rev ($1.26B)
90D Engineering Disclosures0 Published
Investor FAQ CORZ vs PATH Key Questions & Quantitative Answers
As of Nov 16, 2026, UiPath, Inc. (PATH) is the stronger overall head-to-head candidate over Core Scientific, Inc. (CORZ) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). CORZ carries a Unified Composite Score of 40.2/100 (SELL) at $13.47 (16.6x Forward P/E, -2.1% operating margin), whereas PATH carries 58.3/100 (HOLD) at $13.24 (17.4x Forward P/E, 9.4% operating margin). Growth vs. Quality Trade-Off: PATH earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. CORZ 40.2/100 SELL) and 0.86β · 30% Vol risk profile, whereas CORZ leads top-line expansion (+187.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CORZ is currently in a Breakdown options structure phase (RSI 46.9); meanwhile PATH is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CORZ leads the Growth & Scale pillar: CORZ posts +187.1% YoY revenue growth and +61.2% YoY earnings growth on $592M TTM revenue (44.1% gross margin, -2.1% operating margin), compared with PATH at +13.4% YoY revenue growth and N/A YoY earnings growth on $1.72B TTM revenue (82.6% gross margin, 9.4% operating margin). Across the 7-period historical trajectory (FY2020 to FY2026), CORZ cumulative revenue shifted +433.3% while PATH shifted +373.5%. In operating R&D and SG&A reinvestment, CORZ deploys 46.2% of Rev ($274M) (0 90-day corporate R&D disclosures) versus 73.2% of Rev ($1.26B) (0 disclosures) for PATH.
CORZ screens cheaper on headline valuation multiples. CORZ trades at 16.6x Forward P/E, 16.6x Trailing P/E, N/M PEG, and 13.7x EV/Revenue (unreported FCF margin), whereas PATH trades at 17.4x Forward P/E, 19.6x Trailing P/E, 0.41x PEG, and 3.7x EV/Revenue (21.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CORZ (0.0% ROE) versus PATH (20.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CORZ carries 80.6% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.36x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 109% Vol realized risk). By comparison, PATH carries 50.3% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.86β · 30% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.